• 10baggerbamm 楼主 : 作为后续，这是您使用期权的场景，因为您清楚地了解进入时的风险，知道您的损失会是多少。
  不幸的是，6月25日是合同的最远到期日。购买虚值合同，并投放一个买盘，其中没有买盘，这是我要做的事情。所以我会为5美分、0美元、0.10美元、0.20美元的不同数量的合同投放不同的买盘，看看是否成交。
  unfortunately June of 25 is as far out as the contracts go. buying it out of the money contract and throwing a bid in which there's zero bid is what I'm going to do.. so I'll throw different bids in for a nickel $0, .10, .20 different amounts of contracts.. and see if I get filled
  

  举报

  回复
  取消回复

• 10baggerbamm 楼主 : 此外，如果您查看十二月的交易记录，您会发现公司内有四个方进行股票收购，其中三个方收购了6万股，另一个方收购了19万股。
  他们说人们出售股票有各种原因，但他们只买入股票一个。
  as they say people sell stock for variety of reasons but they buy stock for only one.

  举报

  回复
  取消回复

• 10baggerbamm 楼主 : 2024年11月11日 - 下午04:01
  圣地亚哥-（商业新闻社）- 爱文思控股公司（“公司”，“爱文思”，纳斯达克：ARCT），一家专注于开发传染病疫苗和肝脏和呼吸道罕见疾病内的机遇的商业信使RNA药物公司，今天宣布美国食品和药物管理局（FDA）已针对该公司的Investigational New Drug（IND）申请，ARCt-2304自增强mRNA（sa-mRNA）疫苗候选药物，发出了“研究可以继续”通知，以预防由H5N1病毒引起的大流行流感疾病进行主动免疫。 该临床研究由生物医药先进研究和发展局（BARDA）资助，旨在在美国招募大约200名健康成年人。
  SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The clinical study is funded by Biomedical Advanced Research and Development Authority (BARDA) and designed to enroll approximately 200 healthy adults in the United States.

  举报

  回复
  取消回复

• 10baggerbamm 楼主 :

  举报

  回复
  取消回复

• 10baggerbamm 楼主 : https://expose-news.com/2024/12/18/self-replicating-vaccine-trial-in-the-usa/

  举报

  回复
  取消回复

查看更多评论...